Altogether, these observations indicate that dysregulation of Che-1/AATF expression level could be relevant for the transformation process, and strengthen the notion that Che-1/AATF could be considered a valid target for novel anticancer therapeutic approaches either in tumors expressing wild-type p53, or in cancers carrying its mutated forms. This evidence concerns the gene AATF and cancer.